AnaptysBio Inc (ANAB)
22.15
+0.98
(+4.63%)
USD |
NASDAQ |
Nov 22, 15:21
AnaptysBio Total Liabilities (Quarterly): 409.05M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 409.05M |
| June 30, 2024 | 417.50M |
| March 31, 2024 | 358.06M |
| December 31, 2023 | 364.29M |
| September 30, 2023 | 366.94M |
| June 30, 2023 | 368.65M |
| March 31, 2023 | 360.70M |
| December 31, 2022 | 348.28M |
| September 30, 2022 | 340.88M |
| June 30, 2022 | 299.54M |
| March 31, 2022 | 294.42M |
| December 31, 2021 | 286.64M |
| September 30, 2021 | 40.73M |
| June 30, 2021 | 40.84M |
| March 31, 2021 | 14.48M |
| December 31, 2020 | 19.82M |
| September 30, 2020 | 24.51M |
| June 30, 2020 | 20.31M |
| March 31, 2020 | 23.67M |
| December 31, 2019 | 30.19M |
| Date | Value |
|---|---|
| September 30, 2019 | 30.61M |
| June 30, 2019 | 31.73M |
| March 31, 2019 | 26.07M |
| December 31, 2018 | 22.63M |
| September 30, 2018 | 23.44M |
| June 30, 2018 | 21.04M |
| March 31, 2018 | 20.31M |
| December 31, 2017 | 21.78M |
| September 30, 2017 | 20.59M |
| June 30, 2017 | 21.23M |
| March 31, 2017 | 21.00M |
| December 31, 2016 | 22.91M |
| September 30, 2016 | 11.08M |
| June 30, 2016 | 14.10M |
| March 31, 2016 | 12.94M |
| December 31, 2015 | 13.94M |
| September 30, 2015 | 15.30M |
| June 30, 2015 | 16.44M |
| December 31, 2014 | 19.07M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
14.48M
Minimum
Mar 2021
417.50M
Maximum
Jun 2024
221.47M
Average
296.98M
Median
Total Liabilities (Quarterly) Benchmarks
| Eli Lilly and Co | 61.29B |
| Regeneron Pharmaceuticals Inc | 8.116B |
| Ligand Pharmaceuticals Inc | 113.69M |
| Agios Pharmaceuticals Inc | 165.12M |
| ADMA Biologics Inc | 158.73M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 493.42M |
| Shareholders Equity (Quarterly) | 84.37M |
| Current Ratio | 10.23 |